Policy | February 22, 2023
Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The only robotic-arm assisted surgical device to conduct joint replacement with accuracy and better clinical outcomes
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
Monika and Prathmesh’s determination to participate in the Dream Run to increase awareness serves as a testament to life changing effects of organ transplants and importance of organ donation
Dr. Mandaviya and Dharmendra Pradhan dedicate Burns Centre at AIIMS; Lays foundation stone of Critical Care Hospital Building, and award 40 gold medals to meritorious students
The company is one of the most profitable companies manufacturing speciality chemicals in India
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Subscribe To Our Newsletter & Stay Updated
